Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

GeneDx Holdings Corp.

Healthcare US WGS

59.92USD
-1.07(1.75%)

Last update at 2026-06-12T20:00:00Z

Day Range

59.7963.31
LowHigh

52 Week Range

1.1624.40
LowHigh

Fundamentals

  • Previous Close 60.99
  • Market Cap538.45M
  • Volume1398961
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-101.75100M
  • Revenue TTM221.85M
  • Revenue Per Share TTM8.60
  • Gross Profit TTM -26.75000M
  • Diluted EPS TTM-4.97

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -598.03200M -245.39000M -241.34000M -29.70400M
Minority interest - - - -
Net income -548.98000M -245.39000M -246.43600M -30.99100M
Selling general administrative 203.33M 205.99M 100.74M 29.48M
Selling and marketing expenses 134.91M 112.74M 63.18M 39.35M
Gross profit -26.75000M -16.60200M 4.03M 82.78M
Reconciled depreciation 59.31M 21.81M 11.73M 6.41M
Ebit -667.65200M -446.14900M -241.99400M -30.41300M
Ebitda -395.60000M -424.34200M -227.13200M -22.51400M
Depreciation and amortization 272.05M 21.81M 14.86M 7.90M
Non operating income net other 72.83M - - -
Operating income -667.65200M -446.14900M -241.99400M -30.41300M
Other operating expenses 692.20M 658.34M 421.32M 226.59M
Interest expense 3.21M 2.83M 2.47M 0.78M
Tax provision -49.05200M 0.00000M 0.00000M 0.00000M
Interest income 2.54M 0.08M 0.51M 0.99M
Net interest income -0.66600M -2.75600M -1.96800M 0.20M
Extraordinary items - - - -
Non recurring 210.15M - - -
Other items - - - -
Income tax expense -49.05200M -203.59400M 5.10M 1.29M
Total revenue 234.69M 212.19M 179.32M 196.17M
Total operating expenses 430.76M 429.55M 246.02M 113.20M
Cost of revenue 261.44M 228.80M 175.30M 113.39M
Total other income expense net 69.62M 200.76M 0.65M 0.71M
Discontinued operations - - - -
Net income from continuing ops -548.98000M -245.39000M -241.34000M -29.70400M
Net income applicable to common shares -548.98000M -245.39000M -241.34000M -32.74300M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 473.67M 490.94M 554.09M 251.64M -
Intangible assets 172.62M 186.65M - - -
Earning assets - - - - -
Other current assets 10.60M 6.39M 3.80M 4.12M 0.90M
Total liab 245.66M 237.24M 165.99M 581.69M -
Total stockholder equity 228.02M 253.71M 388.10M -330.05100M -
Deferred long term liab - 2.66M - - 0.20M
Other current liab 44.44M 92.12M 52.70M 39.65M 3.06M
Common stock 0.00200M 0.04M 0.02M - -
Capital stock 0.00200M 0.04M 0.02M 0.00000M -
Retained earnings -1300.18800M -1124.42100M -575.44100M -330.05100M -88.71100M
Other liab - 26.68M 53.71M 134.06M 12.97M
Good will - - - - -
Other assets 0.00000M 7.38M 7.83M 14.42M 4.77M
Cash 99.68M 123.93M 400.57M 108.13M -
Cash and equivalents - - - - -
Total current liabilities 58.82M 144.30M 101.28M 73.44M 40.19M
Current deferred revenue - 0.04M 0.47M 1.78M -
Net debt 20.09M -51.54900M -367.72300M -63.10700M -
Short term debt 4.14M 6.12M 3.42M 5.28M -
Short long term debt 0.50M 4.75M - 1.77M -
Short long term debt total 119.77M 72.38M 32.85M 45.02M -
Other stockholder equity 1527.78M 1378.09M 963.52M - -
Property plant equipment - 84.28M 62.72M 63.11M 35.26M
Total current assets 182.34M 212.62M 483.54M 174.11M 163.81M
Long term investments - - - - -
Net tangible assets - 253.71M 388.10M -330.05100M -88.71100M
Short term investments 30.47M - - - -
Net receivables 32.82M 43.34M 26.56M 32.33M 21.64M
Long term debt 52.69M 6.25M 11.00M 18.97M -
Inventory 8.78M 13.66M 33.46M 24.96M 15.98M
Accounts payable 10.24M 46.02M 44.69M 26.74M 17.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.42M - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.04M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -1124.42100M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.43M 7.38M 7.83M 14.42M -
Deferred long term asset charges - - - - -
Non current assets total 291.33M 278.32M 70.55M 77.53M -
Capital lease obligations 66.58M 66.13M 21.85M 24.28M -
Long term debt total - 6.25M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -141.32600M -20.78600M -31.97400M -15.45600M
Change to liabilities 14.99M 24.61M 14.25M 15.19M
Total cashflows from investing activities -141.32600M -20.78600M -31.97400M -15.45600M
Net borrowings -3.29200M -13.46900M 11.73M -1.70900M
Total cash from financing activities 197.31M 493.73M 129.06M 148.01M
Change to operating activities -8.02200M -11.43900M 19.19M -3.38900M
Net income -548.98000M -245.39000M -241.34000M -29.70400M
Change in cash -263.16600M 282.51M 3.95M 113.83M
Begin period cash flow 401.47M 118.96M 115.01M 1.18M
End period cash flow 138.30M 401.47M 118.96M 115.01M
Total cash from operating activities -319.15500M -190.43400M -93.12800M -18.72800M
Issuance of capital stock 0.00000M 442.68M 117.32M 118.82M
Depreciation 59.31M 21.81M 11.73M 6.41M
Other cashflows from investing activities -134.17000M - - -
Dividends paid - - - -
Change to inventory 4.60M -10.62400M -8.97900M -7.97000M
Change to account receivables 5.53M 5.54M -10.61100M -4.56700M
Sale purchase of stock 200.61M - - -
Other cashflows from financing activities 200.61M 64.51M 133.25M 149.72M
Change to netincome 133.89M 25.00M 122.63M 5.31M
Capital expenditures 14.32M 20.79M 31.97M 15.46M
Change receivables 5.53M - - -
Cash flows other operating 13.24M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes -263.16600M - - -
Change in working capital 36.13M 8.08M 13.85M -0.73700M
Stock based compensation 41.98M 219.42M 120.23M 5.48M
Other non cash items 141.53M 1.62M 2.40M -0.17600M
Free cash flow -333.47700M -211.22000M -125.10200M -34.18400M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
WGS
GeneDx Holdings Corp.		 -1.07 1.75% 59.92 - - 1.24 1.10 1.19 -1.7606
VEEV
Veeva Systems Inc Class A		 -2.01 1.24% 159.54 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 -0.04 0.80% 4.98 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock		 0.15 0.24% 63.23 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

View All

Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

GeneDx Holdings Corp.

North Tower, Stamford, CT, United States, 06902

Key Executives

Name Title Year Born
Ms. Katherine A. Stueland President, CEO & Director 1976
Mr. Kevin Feeley Chief Financial Officer NA
Ms. Karen Ponchner Senior VP & Head of Operations NA
Mr. Eric Olivares Ph.D. Chief Product & Technology Officer NA
Mr. Devin K. Schaffer J.D., M.B.A. General Counsel NA
Mr. Paul Kruszka M.D. Chief Medical Officer NA
Ms. Melanie Duquette Chief Growth Officer NA
Sabrina Dunbar Chief of Staff NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.